Adma Biologics (ADMA) Short-term Investments (2014 - 2017)

Adma Biologics has reported Short-term Investments for 4 years, with the latest figure at $1.5 million in Q4 2017.

• For the quarter ending Q4 2017, Short-term Investments fell 72.17% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2017 stood at $1.5 million (down 72.17% YoY), and the FY2017 full-year result was $1.5 million, down 72.17% from the prior year.
• Short-term Investments for Q4 2017 stood at $1.5 million, up from $845389.0 in the prior quarter.
• The five-year high for Short-term Investments was $6.4 million in Q4 2015, with the low at $245000.0 in Q1 2017.
• Historically, Short-term Investments has averaged $3.2 million across 4 years, with a median of $3.1 million in 2014.
• Annual changes were most pronounced in 2015 — Short-term Investments soared 36.87% — and 2017, when it sank 72.17%.
• Adma Biologics' Short-term Investments stood at $4.7 million in 2014, then surged by 36.87% to $6.4 million in 2015, then dropped by 15.36% to $5.4 million in 2016, then slumped by 72.17% to $1.5 million in 2017.
• The last three Short-term Investments figures came in at $1.5 million (Q4 2017), $845389.0 (Q2 2017), and $245000.0 (Q1 2017), per Business Quant data.